The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Listened to the podcast and itseems to me the management don't seem to understand the way the Aim market works with some of the comments made.
I would think a good percentage of investors on the Aim market don't give a diddly squat about the company they are invested in, all they are interested in is making money which ever way they can and when an rns is released followed by another that sticks in the throats of shareholders, that is just cannon fodder for them to unleash all the weapons in their armoury. Sometimes it's aimed at management, who I'm surprised take it to heart being in the position they are in.
After all a lot of investors here have been here for a long long time with no financial gain whatsoever brought by the company so if they deem it necessary to try and make it themselves through the market then so be it.
Yes your quite right Steven49 why were the warrants issued at an all time low for the sp at a price lower instead of higher giving them a chance to earn their reward. Some holders have paid many multiples of the 1p its cost them to get their free Atome shares and they wonder why the sp crashes free shares or no free shares.
At the end of the day when it's all gone through the investors in PPC will be the same investors in Atome.
There a penny look rns dated Nov 2020 when shares issued still say there set too low, but need move on now.
I think that the RNS related to beneficiaries being allocated 1p shares, which they all are, but not getting them at 1p price. I maybe wrong
The warrant holders have therefore done far better than any private investor in ppc that have backed the company for many a year.
Thanks for the link AE may be the investors selling are fed up of the flaky production rns's and have had enough, even with the prospect of a dividend coming their way. As he says each to their own and if they dont have confidence in management they will move on regardless, sp is that proof enough or just the AIM game.
Notice them options were allocated when share price was 1.5 so at time penny was not so bad, but normally options are put ahead of share price be it 1.80 - 2p, not 50% below share price, cashed in now so they can get ATOME shares. Continue hold.